Stephen E Langabeer

List of Publications by Year
in descending order

146	2,531	567281 15	197818 49
papers	citations	h-index	g-index

146	146	146	3036
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantification of atypical BCRâ€ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?. International Journal of Laboratory Hematology, 2022, 44, .	1.3	0
2	Testosterone, erythrocytosis and the JAK2 V617ÂF mutation. Annals of Clinical Biochemistry, 2022, , 000456322210778.	1.6	0
3	Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia. Leukemia Research, 2022, 116, 106823.	0.8	1
4	Screening for latent polycythemia vera in chronic obstructive pulmonary disease-associated erythrocytosis. Respiratory Medicine and Research, 2022, 81, 100914.	0.6	0
5	Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic. Irish Journal of Medical Science, 2021, 190, 27-28.	1.5	6
6	Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?. Blood Cells, Molecules, and Diseases, 2021, 87, 102521.	1.4	2
7	CALR Mutation Underlying Silent Stroke. TH Open, 2021, 05, e174-e175.	1.4	0
8	Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis. Blood Research, 2021, 56, 121-123.	1.3	1
9	Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease. Hematology, Transfusion and Cell Therapy, 2021, 44, 130-130.	0.2	0
10	Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden. Blood Cells, Molecules, and Diseases, 2021, 90, 102593.	1.4	0
11	Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia. Journal of Clinical Pathology, 2021, 74, jclinpath-2020-207246.	2.0	0
12	exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm. EXCLI Journal, 2021, 20, 197-198.	0.7	0
13	The eosinophilic variant of chronic myeloid leukemia.. EXCLI Journal, 2021, 20, 1608-1609.	0.7	1
14	Philadelphia chromosome-positive acute lymphoblastic leukemia with an e14a3 BCR-ABL1 fusion: The role of molecular monitoring. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 166-167.	0.9	0
15	The role of a low erythropoietin level in the diagnosis of JAK2 exon 12-mutated polycythemia vera. Blood Cells, Molecules, and Diseases, 2020, 80, 102377.	1.4	1
16	The JAK2 V617F mutation in breast cancer?. Breast Journal, 2020, 26, 592-592.	1.0	0
17	Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia. Leukemia Research Reports, 2020, 14, 100218.	0.4	1
18	Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare MPL W515S Mutation. Case Reports in Hematology, 2020, 2020, 1-4.	0.4	0

#	Article	IF	Citations
19	Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia. Journal of Clinical Pathology, 2020, 73, 772-772.	2.0	1
20	Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. Leukemia Research Reports, 2020, 13, 100195.	0.4	0
21	Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia. Case Reports in Hematology, 2020, 2020, 1-4.	0.4	2
22	Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?. Blood Research, 2020, 55, 67-68.	1.3	0
23	Strange bedfellows: NPM1 mutations in acute promyelocytic leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.9	0
24	Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic myeloid leukemia. Experimental Oncology, 2020, 42, 78-79.	0.1	1
25	Absence of Polycythemia Vera in Postrenal Transplant Erythrocytosis. Experimental and Clinical Transplantation, 2020, 18, 657-658.	0.5	0
26	Concurrent chronic myeloid leukemia and -mutated myeloproliferative neoplasm. EXCLI Journal, 2020, 19, 86-88.	0.7	1
27	Can post-splenectomy thrombocytosis mask essential thrombocythaemia?. EXCLI Journal, 2020, 19, 773-774.	0.7	0
28	mutations in myeloproliferative neoplasms: An unfolding story. EXCLI Journal, 2020, 19, 1399-1400.	0.7	0
29	The impact of sample processing delay onÂdeep molecular responses in chronic myeloid leukemia. Irish Journal of Medical Science, 2019, 188, 351-352.	1.5	0
30	Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion. Case Reports in Hematology, 2019, 2019, 1-4.	0.4	2
31	Sorafenib for relapsed FLT3 â€ITDâ€positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis. Clinical Case Reports (discontinued), 2019, 7, 2579-2580.	0.5	1
32	Hairy Cell Leukemia Masquerading as Pancytopenia in Pregnancy. Case Reports in Hematology, 2019, 2019, 1-3.	0.4	2
33	Â“JAK2 V617F Mutation in Cervical Cancer Related to HPV & STIsÂ” - Letter. Journal of Cancer Prevention, 2019, 24, 59-60.	2.0	2
34	No indication for CALR mutation analysis in Irish patients presenting with deep vein thrombosis or pulmonary embolism. Irish Journal of Medical Science, 2019, 188, 1459-1460.	1.5	0
35	Aquagenic pruritus and the JAK2 V617F mutation. Clinical and Experimental Dermatology, 2019, 44, e33-e33.	1.3	1
36	Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis. Leukemia Research, 2019, 77, 28-29.	0.8	8

#	Article	IF	Citations
37	Neutrophilia and the JAK2 V617F Mutation. Pathology and Oncology Research, 2019, 25, 437-438.	1.9	0
38	Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. Experimental Oncology, 2019, 41, 82-83.	0.1	2
39	The V617F mutation in retinal vein or artery occlusion. EXCLI Journal, 2019, 18, 127-128.	0.7	1
40	The mutational landscape of atypical chronic myeloid leukemia. EXCLI Journal, 2019, 18, 256-258.	0.7	2
41	Hypercalcemia as a biomarker of myeloproliferative neoplasms?. EXCLI Journal, 2019, 18, 777-778.	0.7	0
42	False-negative CALR mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action. Journal of Clinical Pathology, 2018, 71, 473-474.	2.0	1
43	An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?. European Journal of Internal Medicine, 2018, 52, e37-e38.	2.2	2
44	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. Genetic Testing and Molecular Biomarkers, 2018, 22, 98-103.	0.7	6
45	An acquired NRAS mutation contributes to neutrophilic progression in a patient with primary myelofibrosis. British Journal of Haematology, 2018, 183, 308-310.	2.5	3
46	Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. Clinical and Translational Oncology, 2018, 20, 420-423.	2.4	12
47	Incidental abnormal bone marrow signal on magnetic resonance imaging and reflexive testing for the JAK2 V617F mutation. Quantitative Imaging in Medicine and Surgery, 2018, 8, 881-882.	2.0	1
48	Double-mutant myeloproliferative neoplasms. Medical Oncology, 2018, 35, 137.	2.5	3
49	Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	0
50	Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	0
51	Reflective molecular testing for myeloproliferative neoplasms in patients with elevated serum vitamin B12. Annals of Clinical Biochemistry, 2018, 55, 717-718.	1.6	1
52	Detecting CALR mutations in splanchnic vein thrombosis: Who and how?. Journal of Translational Internal Medicine, 2018, 6, 55-57.	2.5	3
53	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
54	The V617F mutation in isolated neutropenia. EXCLI Journal, 2018, 17, 1-2.	0.7	1

#	Article	IF	Citations
55	Serum ferritin as a biomarker of polycythemia vera?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 94-95.	0.7	0
56	Anagrelide and the CALR mutation allele burden in essential thrombocythemia. Experimental Oncology, 2018, 40, 152-153.	0.1	0
57	The JAK2 V617F mutation in lung cancer: caveat emptor. Experimental Oncology, 2018, 40, 343-344.	0.1	0
58	Who to screen for calreticulin mutations? An audit of real-life practice and review of current evidence. European Journal of Internal Medicine, 2017, 40, e22-e23.	2.2	3
59	Chronic myeloid leukemia with a novel e8a1BCR-ABL1fusion: rapid molecular response with nilotinib. Leukemia and Lymphoma, 2017, 58, 2255-2257.	1.3	0
60	The JAK2 V617F mutation in patients with anaemia. Irish Journal of Medical Science, 2017, 186, 349-350.	1.5	0
61	The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia. Blood Cells, Molecules, and Diseases, 2017, 65, 66-67.	1.4	1
62	Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis. Journal of Clinical Pathology, 2017, 70, 1089-1089.	2.0	6
63	Isolated erythrocytosis associated with a CALR mutation. Blood Cells, Molecules, and Diseases, 2017, 66, 6-7.	1.4	4
64	Splenomegaly and the JAK2 V617F mutation. European Journal of Internal Medicine, 2017, 37, e45-e46.	2.2	1
65	Characterization of a novel variant BCRâ€“ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 85-88.	0.9	3
66	The JAK2 V617F mutation and thrombocytopenia. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 44-45.	0.9	3
67	Chronic Myeloid Leukemia with an e6a2BCR-ABL1Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring. Case Reports in Hematology, 2017, 2017, 1-5.	0.4	2
68	Molecular Profiling: A Case ofZBTB16-RARAAcute Promyelocytic Leukemia. Case Reports in Hematology, 2017, 2017, 1-4.	0.4	5
69	Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia. Case Reports in Hematology, 2017, 2017, 1-3.	0.4	1
70	In Response to â€œBCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requestsâ€• Journal of Oncology Practice, 2017, 13, 283-284.	2.5	1
71	Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, EL01.	0.8	2
72	Hemochromatosis, Erythrocytosis and the p.V617F Mutation. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28, 92-93.	0.7	1

#	Article	IF	Citations
73	Variant BCR-ABL1 fusion genes in adult Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. EXCLI Journal, 2017, 16, 1144-1147.	0.7	2
74	Acute Lymphoblastic Leukemia Arising inCALRMutated Essential Thrombocythemia. Case Reports in Hematology, 2016, 2016, 1-5.	0.4	3
75	Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches. BioMed Research International, 2016, 2016, 1-6.	1.9	8
76	Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics. Jak-stat, 2016, 5, e1248011.	2.2	11
77	CALR mutation profile in Irish patients with myeloproliferative neoplasms. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 112-115.	0.9	0
78	Targeted nextâ€generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 161-163.	2.5	18
79	Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 168-169.	0.9	3
80	Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia. Molecular Diagnosis and Therapy, 2016, 20, 457-461.	3.8	9
81	Capricious CALR mutated clones in myeloproliferative neoplasms. Blood Cells, Molecules, and Diseases, 2016, 57, 110-111.	1.4	1
82	The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis. Pathology and Oncology Research, 2016, 22, 229-230.	1.9	2
83	No Benefit of BCR-ABL1 Screening in Polycythemia. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, EL05.	0.8	0
84	CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review. Annals of Gastroenterology, 2016, 29, 557-558.	0.6	4
85	Molecular diagnostics of myeloproliferative neoplasms. European Journal of Haematology, 2015, 95, 270-279.	2.2	67
86	Getting Hot Under theCALR:What Drives Pediatric Myeloproliferative Neoplasms?. Pediatric Hematology and Oncology, 2015, 32, 513-514.	0.8	0
87	Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation ofJAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation. Case Reports in Hematology, 2015, 2015, 1-4.	0.4	1
88	The e1a3 BCR-ABL1 Fusion Transcript in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Annals of Laboratory Medicine, 2015, 35, 540-541.	2.5	2
89	Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia. Pediatric Blood and Cancer, 2015, 62, 175-176.	1.5	3
90	Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCRâ€“ABL1 fusion. Medical Oncology, 2015, 32, 452.	2.5	11

#	Article	IF	Citations
91	Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia. Molecular Diagnosis and Therapy, 2015, 19, 251-252.	3.8	1
92	Incidence of <scp>CALR</scp> mutations in patients with splanchnic vein thrombosis. British Journal of Haematology, 2015, 168, 459-460.	2.5	36
93	Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia. Archives of Pathology and Laboratory Medicine, 2015, 139, 969-969.	2.5	8
94	Lack of myeloproliferative neoplasm-associatedCALRmutations in acute promyelocytic leukemia. Leukemia and Lymphoma, 2015, 56, 1168-1169.	1.3	0
95	The JAK2 V617F Mutation in Plasma Cell Neoplasms with Co-existing Erythrocytosis. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EL01.	0.8	2
96	Lack of National Consensus for the Molecular Investigation of Myeloproliferative Neoplasms. Irish Medical Journal, 2015, 108, 189-90.	0.0	1
97	JAK2 mutations to the fore in hereditary thrombocythemia. Jak-stat, 2014, 3, e957618.	2.2	3
98	Assessment ofCALRmutations in myelofibrosis patients, post-allogeneic stem cell transplantation. British Journal of Haematology, 2014, 166, 800-802.	2.5	30
99	CALR mutations are rare in childhood essential thrombocythemia. Pediatric Blood and Cancer, 2014, 61, 1523-1523.	1.5	16
100	Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies. Frontiers in Oncology, 2014, 4, 212.	2.8	4
101	Exceptions to the rule in hairy cell leukaemia: implications for molecular diagnostics and targeted therapy. Medical Oncology, 2014, 31, 895.	2.5	1
102	TheJAK2V617F Mutation in Pediatric Myeloproliferative Neoplasms: How and When?. Pediatric Hematology and Oncology, 2014, 31, 138-139.	0.8	1
103	Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. Clinical Chemistry and Laboratory Medicine, 2014, 52, e29-31.	2.3	7
104	Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Familial Cancer, 2014, 13, 659-663.	1.9	4
105	The molecular landscape of childhood myeloproliferative neoplasms. Leukemia Research, 2014, 38, 997-998.	0.8	4
106	The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT. Bone Marrow Transplantation, 2014, 49, 843-844.	2.4	20
107	Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leukemia Research, 2014, 38, 310-315.	0.8	12
108	Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?. Medical Oncology, 2013, 30, 508.	2.5	13

#	Article	IF	Citations
109	An immunophenotypic and molecular diagnosis of composite hairy cell leukaemia and chronic lymphocytic leukaemia. Medical Oncology, 2013, 30, 692.	2.5	6
110	Molecular diagnosis of the myeloproliferative neoplasms: <scp>UK</scp> guidelines for the detection of <scp>JAK</scp>2 <scp>V</scp>617<scp>F</scp> and other relevant mutations. British Journal of Haematology, 2013, 160, 25-34.	2.5	87
111	BCR-ABL1 Kinase Domain Mutation Analysis in an Irish Cohort of Chronic Myeloid Leukemia Patients. Genetic Testing and Molecular Biomarkers, 2013, 17, 170-173.	0.7	3
112	Transient <scp>JAK</scp>2 V617F mutation in an aplastic anaemia patient with a paroxysmal nocturnal haemoglobinuria clone. British Journal of Haematology, 2013, 161, 297-298.	2.5	5
113	Chronic myeloid leukaemia presenting postâ€radiotherapy for prostate cancer: further evidence for an immunosurveillance effect. British Journal of Haematology, 2013, 162, 708-710.	2.5	2
114	Rapid Evolution to Blast Crisis Associated with a Q252HABL1Kinase Domain Mutation in e19a2BCR-ABL1Chronic Myeloid Leukaemia. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	0
115	BRAFV600E-Negative Hairy Cell Leukaemia. Case Reports in Hematology, 2013, 2013, 1-3.	0.4	10
116	Nonfamilial,MPLS505N-Mutated Essential Thrombocythaemia. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	3
117	A prenatal origin of childhood essential thrombocythaemia. British Journal of Haematology, 2013, 163, 676-678.	2.5	5
118	Chronic Myeloid Leukemia with e19a2BCR-ABL1Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring. Case Reports in Hematology, 2012, 2012, 1-3.	0.4	10
119	Referral centre variation in requestingJAK2V617F mutation analysis for the investigation of a myeloproliferative neoplasm. Journal of Clinical Pathology, 2012, 65, 1149-1150.	2.0	10
120	A novel, variant BCRâ€ABL1 transcript not detected by standard realâ€time quantitative PCR in a patient with chronic myeloid leukaemia. International Journal of Laboratory Hematology, 2012, 34, e1-2.	1.3	3
121	Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. International Journal of Laboratory Hematology, 2012, 34, 417-421.	1.3	20
122	Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leukemia Research, 2012, 36, 483-484.	0.8	31
123	The Incidence of Co-Existing <i>BCR-ABL1</i> and <i>JAK2</i> V617F Rearrangements: Implications for Molecular Diagnostics. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2012, 18, 20-21.	1.2	2
124	A novel e8a2BCRâ€“ABL1fusion with insertion ofRALGPS1exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2011, 52, 919-921.	1.3	6
125	Guidelines for the measurement of BCRâ€ABL1 transcripts in chronic myeloid leukaemia. British Journal of Haematology, 2011, 153, 179-190.	2.5	94
126	Molecular response to first line nilotinib in a patient with e19a2 BCRâ€“ABL1 chronic myeloid leukemia. Leukemia Research, 2011, 35, e169-e170.	0.8	12

#	Article	IF	Citations
127	Complete molecular remission in a polycythaemia vera patient 12Âyears after discontinuation of interferon-alpha. Annals of Hematology, 2011, 90, 233-234.	1.8	4
128	Acute Lymphoblastic Leukaemia with an e1a3 <i>BCR-ABL1</i> Fusion. Acta Haematologica, 2011, 126, 214-215.	1.4	9
129	Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCRâ€“ABL chronic myeloid leukemia. Leukemia Research, 2010, 34, e176-e177.	0.8	0
130	Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts. Leukemia Research, 2010, 34, e204-e205.	0.8	11
131	A Doctor(s) dilemma: ETV6â€ABL1 positive acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 151, 101-102.	2.5	15
132	Prevalence of the JAK2 V617F and MPL Mutations in Stroke, Abdominal and Peripheral Venous Thrombosis. Acta Haematologica, 2010, 124, 160-161.	1.4	5
133	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.. Blood, 2010, 116, 3427-3427.	1.4	6
134	Identification of <i>MPL</i> W515L/K Mutations in Patients with Primary Myelofibrosis and Essential Thrombocythaemia by Allele-Specific Polymerase Chain Reaction. Acta Haematologica, 2009, 121, 221-222.	1.4	7
135	Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.. Blood, 2009, 114, 3294-3294.	1.4	5
136	Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?. Blood, 2008, 112, 4356-4357.	1.4	12
137	Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Irish Journal of Medical Science, 2007, 176, 105-109.	1.5	6
138	Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 1394-1396.	1.3	14
139	AML with t(8;21) and trisomy 4: possible involvement of c-kit?. Leukemia, 2003, 17, 1915-1915.	7.2	7
140	Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia. Leukemia Research, 2003, 27, 869-870.	0.8	7
141	Mutations of theAML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes and Cancer, 2002, 34, 24-32.	2.8	53
142	The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001, 98, 1752-1759.	1.4	1,392
143	Screening for mutations of Bcl10 in leukaemia. British Journal of Haematology, 2000, 109, 611-615.	2.5	11
144	c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 1999, 105, 894-900.	2.5	229

#	Article	IF	Citations
145	IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia. Cytokines, Cellular & Molecular Therapy, 1998, 4, 7-9.	0.3	1
146	Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. British Journal of Haematology, 1997, 96, 490-492.	2.5	15